Quantcast

Latest zolpidem Stories

2011-05-05 15:35:00

POINT RICHMOND, Calif., May 5, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, May 16, 2011 at 4:30 p.m. Eastern Time to discuss its first quarter 2011 financial results. The conference call will follow the release of the...

2011-03-09 07:02:00

POINT RICHMOND, Calif., March 9, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, March 16, 2011 at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2010 financial results. The conference call will...

2011-02-08 15:05:00

POINT RICHMOND, Calif., Feb. 8, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the BIO CEO & Investor Conference in New York on February 15, 2011 at 3:30 p.m. EST. A live audio webcast and...

2011-01-31 07:02:00

POINT RICHMOND, Calif., Jan. 31, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that the U.S. Food and Drug Administration (FDA) has classified the recent Intermezzo® New Drug Application (NDA) resubmission as a complete Class 2 response and assigned a Prescription Drug User Fee Act (PDUFA) action date of July 14, 2011 for the completion of the NDA review. (Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO) About...

2011-01-13 14:55:04

Adults who take one of the world's most commonly prescribed sleep medications are significantly more at risk for nighttime falls and potential injury, according to a new study by the University of Colorado at Boulder. The study, which involved 25 healthy adults, showed 58 percent of the older adults and 27 percent of the young adults who took a hypnotic, sleep-inducing drug called zolpidem showed a significant loss of balance when awakened two hours after sleep. The findings are important...

2010-11-08 14:54:26

When sleep doesn't come easily, some people turn to what they think is an easy solution "“ sleeping pills. But according to a Baylor College of Medicine sleep expert, sleep medications "“ whether prescription or over-the-counter "“ shouldn't be taken lightly. "All medications have side effects that need to be weighed whenever you take them," cautioned Dr. Phil Alapat, assistant professor of pulmonary, critical care and sleep medicine at BCM and medical director of the BCM...

2010-10-18 23:19:00

POINT RICHMOND, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced its preliminary analysis of data from the recently completed Intermezzo® 3.5 mg (zolpidem tartrate sublingual tablet) highway driving study. Transcept is developing Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. In the...

2010-10-18 17:00:00

MORRISTOWN, N.J., Oct. 18 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV. Distribution of the product has commenced. As the first company to file an ANDA that contained a paragraph IV certification for Ambien® CR 6.25mg, Actavis has been awarded 180-day exclusivity to market this...

2010-09-29 15:05:00

POINT RICHMOND, Calif., Sept. 29 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the BIO Investor Forum in San Francisco on October 6, 2010 at 3:00 p.m. PDT. A live audio webcast and replay of this...

2010-09-20 04:29:00

DALLAS, September 20, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Insomnia Market Forecast Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/reports/33201-insomnia-market-forecast.html Search More Then 50000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/) Browse All Datamonitor Research Reports at http://www.reportsandreports.com/Publishers/datamonitor/ The availability of...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin